Recruiting NCT07260708
Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: TQB2922 injection (subcutaneous injection).
- Who it may be relevant to
- Registry conditions: Advanced Cancers. Basic parameters: 18 years — 75 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Phase I Clinical Study to Evaluate The Safety and Pharmacokinetics of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers
Overview
This is a Phase I clinical study aimed at evaluating the safety and pharmacokinetics of TQB2922 subcutaneous injection in patients with advanced cancers.
Interventions
- Drug TQB2922 injection (subcutaneous injection)
TQB2922 is a bispecific antibody against Epidermal Growth Factor Receptor (EGFR)/c-Met.
Primary outcome measures
- Time to Peak Concentration [Time frame: Cycle 1 Day 1:predose, 2, 6, 10, 24, 48, 72 hours after infusion, Cycle 1 Day 8, 15, 22:predose; Cycle 2 Day1: predose, 2, 6 h, 10, 24, 48, 72, 168 hours after infusion; Cycle 2 Day 15;Day 1 on Cycle 4, Cycle 6,Cycle 8: predose (each cycle is 28 days)]
- Peak concentration [Time frame: Cycle 1 Day 1:predose, 2, 6, 10, 24, 48, 72 hours after infusion, Cycle 1 Day 8, 15, 22:predose; Cycle 2 Day1: predose, 2, 6 h, 10, 24, 48, 72, 168 hours after infusion; Cycle 2 Day 15;Day 1 on Cycle 4, Cycle 6,Cycle 8: predose (each cycle is 28 days)]
- half-life (T1/2) [Time frame: Cycle 1 Day 1:predose, 2, 6, 10, 24, 48, 72 hours after infusion, Cycle 1 Day 8, 15, 22:predose; Cycle 2 Day1: predose, 2, 6 h, 10, 24, 48, 72, 168 hours after infusion; Cycle 2 Day 15;Day 1 on Cycle 4, Cycle 6,Cycle 8: predose (each cycle is 28 days)]
- The area under the curve (AUC0-∞） [Time frame: Cycle 1 Day 1:predose, 2, 6, 10, 24, 48, 72 hours after infusion, Cycle 1 Day 8, 15, 22:predose; Cycle 2 Day1: predose, 2, 6 h, 10, 24, 48, 72, 168 hours after infusion; Cycle 2 Day 15;Day 1 on Cycle 4, Cycle 6,Cycle 8: predose (each cycle is 28 days)]
- The area under the curve (AUC0-t) [Time frame: Cycle 1 Day 1:predose, 2, 6, 10, 24, 48, 72 hours after infusion, Cycle 1 Day 8, 15, 22:predose; Cycle 2 Day1: predose, 2, 6 h, 10, 24, 48, 72, 168 hours after infusion; Cycle 2 Day 15;Day 1 on Cycle 4, Cycle 6,Cycle 8: predose (each cycle is 28 days)]
- Elimination Rate [Time frame: Cycle 1 Day 1:predose, 2, 6, 10, 24, 48, 72 hours after infusion, Cycle 1 Day 8, 15, 22:predose; Cycle 2 Day1: predose, 2, 6 h, 10, 24, 48, 72, 168 hours after infusion; Cycle 2 Day 15;Day 1 on Cycle 4, Cycle 6,Cycle 8: predose (each cycle is 28 days)]
- Apparent Oral Clearance [Time frame: Cycle 1 Day 1:predose, 2, 6, 10, 24, 48, 72 hours after infusion, Cycle 1 Day 8, 15, 22:predose; Cycle 2 Day1: predose, 2, 6 h, 10, 24, 48, 72, 168 hours after infusion; Cycle 2 Day 15;Day 1 on Cycle 4, Cycle 6,Cycle 8: predose (each cycle is 28 days)]
- Apparent Volume of Distribution [Time frame: Cycle 1 Day 1:predose, 2, 6, 10, 24, 48, 72 hours after infusion, Cycle 1 Day 8, 15, 22:predose; Cycle 2 Day1: predose, 2, 6 h, 10, 24, 48, 72, 168 hours after infusion; Cycle 2 Day 15;Day 1 on Cycle 4, Cycle 6,Cycle 8: predose (each cycle is 28 days)]
- Trough Concentration [Time frame: Cycle 1 Day 1:predose, 2, 6, 10, 24, 48, 72 hours after infusion, Cycle 1 Day 8, 15, 22:predose; Cycle 2 Day1: predose, 2, 6 h, 10, 24, 48, 72, 168 hours after infusion; Cycle 2 Day 15;Day 1 on Cycle 4, Cycle 6,Cycle 8: predose (each cycle is 28 days)]
- Accumulation Ratio [Time frame: Cycle 1 Day 1:predose, 2, 6, 10, 24, 48, 72 hours after infusion, Cycle 1 Day 8, 15, 22:predose; Cycle 2 Day1: predose, 2, 6 h, 10, 24, 48, 72, 168 hours after infusion; Cycle 2 Day 15;Day 1 on Cycle 4, Cycle 6,Cycle 8: predose (each cycle is 28 days)]
Secondary outcome measures (5)
- Adverse Events (AE) rate [Time frame: From date of the first dose until the date of 30 days after last dose or new anti-tumor treatment, whichever came first]
- Objective Response Rate (ORR) [Time frame: Up to 2 years]
- Duration of Response (DOR) [Time frame: Up to 3 years]
- Progression-free survival (PFS) [Time frame: Up to 3 years]
- Incidence of anti-drug antibody (ADA) [Time frame: From the time of informed consent signed through 90 days after the last dose.]
Eligibility criteria
Inclusion criteria
- Subjects voluntarily joined this study, signed the informed consent form, and had good compliance；
- 18-75 yeas old；
- Eastern Cooperative Oncology Group Performance Status (ECOG) score: 0-1;
- Expected survival of more than 12 weeks；
- Histologically or cytologically diagnosed with advanced non-squamous non-small cell lung cancer
- Subjects in the monotherapy introduction stage need to have received standard treatment or lack effective treatment.
- There must be at least one measurable lesion within the radiotherapy area that can be clearly classified as progressive according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST1.1) criteria.
- Major organs are functioning well；
- Female and male subjects of childbearing potential should agree to practice contraception for the duration of the study and for 6 months after the end of the study.
Exclusion criteria
- Current concomitant presence of other malignancies within 5 years prior to the first dose；
- At the time of initiating the study of treatment, the adverse reactions caused by previous anti-tumor treatments failed to recover to a CTCAE 5.0 score of grade 1 or below.
- Patients who had received major surgical treatment within 4 weeks prior to the first study, had obvious traumatic injuries, or were expected to undergo major surgery during the study treatment period, or had long-term unhealed wounds or fractures.
- Hyperactive or venous thrombosis events occurred within 6 months before the first administration;
- Major cardiovascular diseases;
- Active hepatitis
- Those with a history of psychotropic drug abuse who are unable to quit or have mental disorders.
- There was an active infection (≥ Common Terminology Criteria for Adverse Events version 5.0 (CTCAE5.0) score of grade 2) within 2 weeks before the first administration;
- Patients with renal failure requiring hemodialysis or peritoneal dialysis;
- Patients who have a history of immune deficiency.
- Patients who have epilepsy and need treatment;
- Evidence of a previous history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis requiring steroid treatment, or any clinically active interstitial lung disease.
- Those who have participated in and used other anti-tumor clinical trial drugs within 4 weeks before the first treatment.
- Pregnant or lactating women.
- There is any serious or uncontrolled systemic disease.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
China · 11 centers
- Sun Yat-sen University Cancer Center — Guangzhou
- Henan Cancer Hospital — Zhengzhou
- The First Affiliated Hospital of Zhengzhou University — Zhengzhou
- Hunan Cancer Hospital — Changsha
- Nanjing Drum Tower Hospital — Nanjing
- The First Affiliated Hospital of Nanchang University — Nanchang
- Affiliated Zhongshan Hospital of Dalian University — Dalian
- Shandong Cancer Hospital — Jinan
- … and 3 more centers
Identifiers
NCT: NCT07260708 · TQB2922-I-02